CN107648308A - A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof - Google Patents
A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof Download PDFInfo
- Publication number
- CN107648308A CN107648308A CN201710903023.7A CN201710903023A CN107648308A CN 107648308 A CN107648308 A CN 107648308A CN 201710903023 A CN201710903023 A CN 201710903023A CN 107648308 A CN107648308 A CN 107648308A
- Authority
- CN
- China
- Prior art keywords
- externally
- skin disease
- applied ointment
- disease treatment
- pet skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 86
- 208000017520 skin disease Diseases 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims abstract description 43
- 229960004125 ketoconazole Drugs 0.000 claims abstract description 43
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract description 41
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960000282 metronidazole Drugs 0.000 claims abstract description 41
- 235000019477 peppermint oil Nutrition 0.000 claims abstract description 41
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000002562 thickening agent Substances 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 238000003756 stirring Methods 0.000 claims description 46
- 239000003995 emulsifying agent Substances 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 26
- 235000000914 Solidago virgaurea Nutrition 0.000 claims description 21
- 244000197975 Solidago virgaurea Species 0.000 claims description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 239000006210 lotion Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 229940099259 vaseline Drugs 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 4
- IJMWOMHMDSDKGK-UHFFFAOYSA-N Isopropyl propionate Chemical compound CCC(=O)OC(C)C IJMWOMHMDSDKGK-UHFFFAOYSA-N 0.000 claims description 3
- 241000220287 Sedum rubrotinctum Species 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 240000006021 Solidago canadensis Species 0.000 description 8
- 235000003657 Solidago canadensis Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 241000607059 Solidago Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000005034 decoration Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 240000004183 Bongardia chrysogonum Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a kind of externally-applied ointment for pet skin disease treatment and preparation method thereof.It is provided by the present invention to be used for the sick externally-applied ointment treated of pet skin with ketoconazole, metronidazole, peppermint oil, Herba Solidaginis extract, and auxiliary material for raw material components, by the complex role between each component, so as to play good pet skin disease therapeutic effect.It is simple to operate meanwhile preparation method processing step of the present invention is easy, suitable for industrial-scale production.
Description
Technical field
The present invention relates to field of veterinary, in particular to a kind of externally-applied ointment for pet skin disease treatment and its
Preparation method.
Background technology
With the modern improvement of people's living standards, raising pet has become a kind of leisure way, while can also make
For a kind of spiritual sustenance.However, while people are accompanied, the germ entrained by pet can also endanger the health of people.Remove
Outside commonly known rabies, busy can also infect of pet skin disease gives people, such as favus of the scalp, psoriasis, mound property nettle rash or itches
Rash, allergic dermatitis, C. neoformans infection etc..
Solidago Canadensis (Solidago canadensis) originates in North America, is composite family Solidago perennial grass
This plant.Nineteen thirty-five introduces China as flower plant, initially cultivates in the with of Shanghai and Nanjing one, the rear raw field of ease.Canada one
Branch chrysanthemum with root-like stock, seed two ways due to being bred, thus its breeding and survival ability are extremely strong, simultaneously because lacking day
Therefore native Reel, nutrient, moisture and space easily are competed with surrounding plants as sociales, cause other species to exit so that disappearing
Die, bio-diversity is constituted a threat to, it has also become be domestic at present to endanger one of Invasive Alien Species the most serious.
In order to prevent further spreading, the domestic Control Technology to Solidago Canadensis carried out it is widely studied, wherein
Including its comprehensive utilization technique, i.e., such as extract the endophytic active component and be used.Relax one's efforts etc. (2006) have studied
The chemical composition and its antibacterial activity of Solidago Canadensis volatile oil, identify Solidago Canadensis volatile oil it is multiple into
Point, and its bacteriostatic activity is analyzed, as a result show big myrcene D (Germ arcene D) to Escherichia coli and withered grass
Bacillus has significant inhibitory action.Wang Kaijin etc. (2006) analyzes Solidago Canadensis with GC-MS GC-MSs
The chemical composition and content of essential oil, and determine antibacterial activity of the essential oil to 6 kinds of agriculture disease funguses.
Although being found that many components with physiologically active in Solidago Canadensis at present, existing research is only
It is to demonstrate it to have certain physiologically active, and does not carry out can be applied to pet skin disease using the extract of the plant controlling
The bactericide product for the treatment of；In addition, though though Solidago Canadensis extract has certain antibacterial activity, as a kind of sterilization
Agent its still suffer from activity it is too low the shortcomings of.
In view of this, it is special to propose the present invention.
The content of the invention
The first object of the present invention is to provide a kind of externally-applied ointment for pet skin disease treatment, external application in the present invention
In ointment, using Herba Solidaginis extract as main functional component, and coordinate ketoconazole, metronidazole, and the drug effect thing such as peppermint oil
Matter is used in conjunction with, so as to play good pet skin disease therapeutic effect.
The second object of the present invention is to provide a kind of preparation of the described externally-applied ointment for being used for pet skin disease treatment
Method.
The third object of the present invention is to provide a kind of medicine for including the externally-applied ointment for pet skin disease treatment
Thing or pharmaceutical composition.
In order to realize the above-mentioned purpose of the present invention, spy uses following technical scheme：
A kind of externally-applied ointment for pet skin disease treatment, the externally-applied ointment for pet skin disease treatment are main
It is made up of following components：Ketoconazole, metronidazole, peppermint oil, Herba Solidaginis extract, and auxiliary material；Preferably, the solidago plant
Flower extract is one or more of in goldenrod water extract, goldenrod leaf essential oil, or goldenrod volatile oil
Mixture.
Preferably, in the externally-applied ointment of the present invention for pet skin disease treatment, the auxiliary material includes thickener, breast
Agent and water.
Preferably, in the externally-applied ointment of the present invention for pet skin disease treatment, the emulsifying agent includes：Dodecane
One or more in base sodium sulphate, Tween-80, Arlacel-80, or triethanolamine；And/or the thickener includes：It is single hard
It is one or more of in glycerol, stearyl alcohol, vaseline, atoleine, vitamin E oil, isopropyl myristate.
Preferably, according to percent by weight, the present invention is used for the externally-applied ointment of pet skin disease treatment mainly by following
Component is made：Ketoconazole 1~10%, metronidazole 1~10%, peppermint oil 1~10%, Herba Solidaginis extract 5~50%, and
Auxiliary material 20~90%.
Preferably, according to percent by weight, the present invention is used for the externally-applied ointment of pet skin disease treatment mainly by following
Component is made：Ketoconazole 1~10%, metronidazole 1~10%, peppermint oil 1~10%, Herba Solidaginis extract 5~50%, thickening
Agent 2~30%, emulsifying agent 1~10%, and water 15~50%.
Meanwhile present invention also offers the preparation method of the externally-applied ointment for pet skin disease treatment, it includes
Following steps：Mix, stir after each component is dissolved respectively, sticky lotion is obtained after cooling, it is as described to be used for pet
The externally-applied ointment for the treatment of skin disease.
Preferably, the preparation method of the externally-applied ointment of the present invention for pet skin disease treatment comprises the following steps：
(a) after thickener is mixed, it is heated to being completely dissolved, stirs, obtains thickener mixed system；(b) emulsifying agent is added
Stirring and dissolving in water after heating, then add metronidazole, peppermint oil and Herba Solidaginis extract, stirring and dissolving；(c) will be dilute
After hydrochloric acid heating, ketoconazole stirring and dissolving is added；(d) step (b), (c) resulting solution are added in thickener mixed system, stirred
Mixing is mixed, sticky lotion, the as externally-applied ointment for pet skin disease treatment are obtained after cooling.
Preferably, the preparation method of the externally-applied ointment of the present invention for pet skin disease treatment comprises the following steps：
(a) after mixing emulsifying agent, thickener, it is heated to raw material and is completely dissolved, stir, obtain thickener mixed system；(b) will
Metronidazole, peppermint oil and Herba Solidaginis extract add stirring and dissolving in the water after heating；(c) after watery hydrochloric acid is heated, add
Enter ketoconazole stirring and dissolving；(d) step (b), (c) resulting solution are added in thickener mixed system, are stirred, cooled down
After obtain sticky lotion, the as externally-applied ointment for pet skin disease treatment.
Preferably, the preparation method of the externally-applied ointment of the present invention for pet skin disease treatment comprises the following steps：
(a) after thickener is mixed, it is heated to raw material and is completely dissolved, stir, obtains thickener mixed system；(b) by emulsifying agent
Dissolved in the water added after heating, obtain emulsifier solution；(c) metronidazole, peppermint oil and Herba Solidaginis extract are added
Stirring and dissolving in water after heating；(d) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；(e) emulsifier solution is added
Enter and stirred in thickener mixed system, then, addition step (c), (d) resulting solution are stirred, and sticky cream is obtained after cooling
Body, the as externally-applied ointment for pet skin disease treatment.
Further, present invention also offers the medicine or drug regimen for being used for pet skin disease treatment comprising the present invention
Thing.
Compared with prior art, beneficial effects of the present invention are：
(1) in the present invention, by Herba Solidaginis extract and metronidazole, ketoconazole and peppermint oil etc., function ingredients are compound makes
With, by the complex role between component, the bactericidal activity of externally-applied ointment of the present invention can be effectively improved, and can be to pet skin
Disease is effectively treated；
(2) in preparation method of the present invention, used steps flow chart is easy, and simple to operate, without using large-scale instrument
Equipment, and this is also beneficial to large-scale production and prepared；
Meanwhile by being mixed again after different material is dissolved respectively, the abundant dissolving of each raw material is also beneficial to, and
Further uniform mixture, while be also beneficial to further improve drug effect and therapeutic effect.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the present invention.It is unreceipted specific in embodiment
Condition person, the condition suggested according to normal condition or manufacturer are carried out.Agents useful for same or the unreceipted production firm person of instrument, it is
The conventional products that can be obtained by commercially available purchase.
In view of effective utilization for Herba Solidaginis extract at present and insufficient, and individually Herba Solidaginis extract institute
There is the technical problem such as drug effect deficiency, it is soft that spy of the present invention provides a kind of new external application for being used for pet skin disease treatment
Cream, and the skin disease triggered by fungal infection etc. can be realized and fast and effectively treated, while will not also bring any pair
Effect, will not also be produced repeatedly.
Specifically, the externally-applied ointment provided by the present invention for pet skin disease treatment is made up of following components：Ketone health
Azoles, metronidazole, peppermint oil, Herba Solidaginis extract, and auxiliary material；
Preferably, the Herba Solidaginis extract is goldenrod water extract, goldenrod leaf essential oil, or solidago plant
One or more of mixtures in flowers volatile oil.
And by the way that Herba Solidaginis extract and ketoconazole, metronidazole, and the function ingredients such as peppermint oil are used in combination, and
By the complex role between each component, the bactericidal effect of Herba Solidaginis extract can be effectively improved, so as to solve goldenrod
Extract the application caused by bactericidal activity is low is limited the problems such as, and then be also beneficial to goldenrod it is further effectively
Utilize.
Preferably, in the externally-applied ointment of the present invention for pet skin disease treatment, auxiliary material used is thickener, emulsification
Agent and water；
It is furthermore preferred that the emulsifying agent is in lauryl sodium sulfate, Tween-80, Arlacel-80, or triethanolamine
It is one or more of；
It is furthermore preferred that the thickener be glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil,
It is one or more of in isopropyl myristate.
It is further preferred that according to percent by weight, the externally-applied ointment that the present invention is used for pet skin disease treatment is main
It is made up of following components：
Ketoconazole 1~10%, such as can be, but it is not limited to 2,3,5,7, or 9% etc.；Metronidazole 1~10%, such as
It can be, but be not limited to 2,3,5,7, or 9% etc.；Peppermint oil 1~10%, such as can be, but 2,3,5,7 are not limited to, or
Person 9% etc.；Herba Solidaginis extract 5~50%, such as can be, but be not limited to 8,10,12,15,18,20,22,25,28,
30th, 32,35,38,40,42,45, or 47% etc.；And auxiliary material 20~90%, such as can be, but be not limited to 25,30,
35th, 40,45,50,55,60,65,70,75,80, or 85% etc.；
Condition is that each component dosage sum is 100%；
And by the further selection and adjustment to each component dosage, can also effectively improve externally-applied ointment of the present invention for
The therapeutic effect of pet skin disease.
Still more preferably, according to percent by weight, the present invention is used for the externally-applied ointment master of pet skin disease treatment
To be made up of following components：
Ketoconazole 1~10%, such as can be, but it is not limited to 2,3,5,7, or 9% etc.；Metronidazole 1~10%, such as
It can be, but be not limited to 2,3,5,7, or 9% etc.；Peppermint oil 1~10%, such as can be, but 2,3,5,7 are not limited to, or
Person 9% etc.；Herba Solidaginis extract 5~50%, such as can be, but be not limited to 8,10,12,15,18,20,22,25,28,
30th, 32,35,38,40,42,45, or 47% etc.；Thickener 2~30%, such as can be, but be not limited to 5,8,10,12,
15th, 18,20,22, or 25% etc.；Emulsifying agent 1~10%, such as can be, but it is not limited to 2,3,5,7, or 9% etc.；With
And water 15~50%, such as can be, but it is not limited to 20,25,30,35,40, or 45% etc.；
Condition is that each component dosage sum is 100%.
By the adjustment and optimization to each component raw material dosage, it also further can improve and optimize externally-applied ointment of the present invention
For the therapeutic effect of pet skin disease.
The operating procedure flow of the preparation method of externally-applied ointment of the present invention is also more simple, is by each component classification mixing
Can.
It is further preferred that different charging sequence can also be used further, and enter referring in particular to following three kinds of methods
The preparation of row externally-applied ointment of the present invention：
(I)：
(a) after thickener is mixed, it is heated to being completely dissolved, stirs, obtains thickener mixed system；
Preferably, in this step, the temperature of heating is 60~70 DEG C, it is furthermore preferred that the temperature of heating is 65 DEG C, and preferably
Insulation at the heating temperature；
(b) emulsifying agent is added into stirring and dissolving in the water after heating, then adds metronidazole, peppermint oil and goldenrod
Extract, stirring and dissolving；
Preferably, the heating-up temperature of water is 70~85 DEG C；It is furthermore preferred that the heating-up temperature of water is 80 DEG C, and preferably exist
It is incubated under solution temperature；
(c) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
Preferably, in this step, the temperature of watery hydrochloric acid heating is 60~70 DEG C, and is preferably incubated at such a temperature；
(d) step (b), (c) resulting solution are added in thickener mixed system, stirs and evenly mixs, obtained after cooling sticky
Lotion, the as externally-applied ointment for pet skin disease treatment；
(II)
(a) after mixing emulsifying agent, thickener, it is heated to raw material and is completely dissolved, stir, obtain thickener mixture
System；
Preferably, in this step, the temperature of heating is 60~70 DEG C, it is furthermore preferred that the temperature of heating is 65 DEG C, and preferably
Insulation at the heating temperature；
(b) metronidazole, peppermint oil and Herba Solidaginis extract are added into stirring and dissolving in the water after heating；
Preferably, in this step, the heating-up temperature of water is 70~85 DEG C；It is furthermore preferred that the heating-up temperature of water is 80 DEG C, and
Preferably it is incubated under the temperature conditionss；
(c) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
Preferably, in this step, the temperature of watery hydrochloric acid heating is 60~70 DEG C, and is preferably protected under the temperature conditionss
Temperature；
(d) step (b), (c) resulting solution are added in thickener mixed system, is stirred, is obtained after cooling sticky
Lotion, the as externally-applied ointment for pet skin disease treatment.
(III)：
(a) after thickener is mixed, it is heated to raw material and is completely dissolved, stir, obtains thickener mixed system；
Preferably, in this step, the temperature of heating is 60~70 DEG C, it is furthermore preferred that the temperature of heating is 65 DEG C；
(b) dissolved in the water for adding emulsifying agent after heating, obtain emulsifier solution；
Preferably, the heating-up temperature of water is 60~70 DEG C, and is preferably incubated under the temperature conditionss；
Preferably, in this step, the dosage of water is the 10% of the recipe quantity of water；
(c) metronidazole, peppermint oil and Herba Solidaginis extract are added into stirring and dissolving in the water after heating；
Preferably, in this step, the heating-up temperature of water is 70~85 DEG C；It is furthermore preferred that the temperature of water heating is 80 DEG C, and
Preferably it is incubated under the temperature conditionss；
Preferably, in this step, the dosage of water is the 90% of the recipe quantity of water；
(d) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
Preferably, in this step, the temperature of watery hydrochloric acid heating is 60~70 DEG C, and is preferably incubated at such a temperature；
(e) emulsifier solution is added in thickener mixed system and stirred, then add step (c), (d) resulting solution
It is stirred, sticky lotion, the as externally-applied ointment for pet skin disease treatment is obtained after cooling.
And in three kinds as described above specific methods, it is preferred that preferably to control Aqueous Phase Raw Material (to be dissolved in water/dilute
The ketoconazole of hydrochloric acid, metronidazole, peppermint oil and material solution obtained by a flower extract) temperature be higher than or with thickening
The temperature (i.e. the mixture system of thickener dissolving mixt system/thickener and emulsifying agent) of agent mixed system, and this also has
Beneficial to the mixing and emulsification of different phase raw material, be advantageous to the shaping of product；
Meanwhile dissolved ketoconazole with hot dilute hydrochloric acid solution, its dissolved efficiency can be also effectively improved, and be advantageous to
Its in the solution scattered, and the therapeutic effect for pet skin disease can be improved.
Further, during actual therapeutic, externally-applied ointment of the present invention can be individually applied to affected part and is treated；
The one or more in externally-applied ointment of the present invention and other painting or injection class medicines for oral administration, outer can be either used in combination,
And for treating for skin disease such as dermatitis.
Embodiment 1
According to mass percent：Ketoconazole 1%, metronidazole 2%, peppermint oil 1%, goldenrod leaf essential oil 35%, thickening
Agent 5%, emulsifying agent 5%, and the water of surplus, appropriate each raw material is weighed respectively；
Wherein, the thickener is glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, Pork and beans
The mixture of cool isopropyl propionate；
The emulsifying agent is lauryl sodium sulfate；
Then, it is prepared as follows the externally-applied ointment of embodiment 1：
(a) by glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, and myristic acid isopropyl
Ester is mixed and heated to 65 DEG C, after raw material is completely dissolved, and stirs, and obtains thickener mixed system, and protected under the conditions of 65 DEG C
Temperature；
(b) lauryl sodium sulfate is added to stirring and dissolving in 80 DEG C of water, then adds metronidazole, peppermint oil and one
Branch chrysanthemum leaf essential oil, stirring and dissolving, and be incubated under the conditions of 80 DEG C；
(c) after appropriate watery hydrochloric acid being heated into 60 DEG C, ketoconazole stirring and dissolving is added, and be incubated under the conditions of 60 DEG C；
(d) step (b), (c) resulting solution are added in thickener mixed system, is stirred, is obtained after cooling sticky
The externally-applied ointment for being used for pet skin disease treatment of lotion, as embodiment 1.
Embodiment 2
According to mass percent：Ketoconazole 1%, metronidazole 2%, peppermint oil 1%, goldenrod volatile oil 40%, thickening
Agent 6%, emulsifying agent 6%, and the water of surplus, appropriate each raw material is weighed respectively；
Wherein, the thickener be glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, and
Isopropyl myristate；
The emulsifying agent is Tween-80 and Arlacel-80；
Then, it is prepared as follows the externally-applied ointment of embodiment 2：
(a) by Tween-80, Arlacel-80, glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil,
And isopropyl myristate is mixed and heated to 65 DEG C, after raw material is completely dissolved, and stirs, thickener mixed system is obtained；
(b) metronidazole, peppermint oil and goldenrod leaf essential oil are added to stirring and dissolving in 80 DEG C of water, and in 80 DEG C of bars
It is incubated under part；
(c) after appropriate watery hydrochloric acid being heated into 60 DEG C, ketoconazole stirring and dissolving is added, and be incubated under the conditions of 60 DEG C；
(d) step (b), (c) resulting solution are added in thickener mixed system, is stirred, is obtained after cooling sticky
The externally-applied ointment for being used for pet skin disease treatment of lotion, as embodiment 2.
Embodiment 3
According to mass percent：Ketoconazole 1%, metronidazole 2%, peppermint oil 1%, goldenrod water extract 50%, increase
Thick dose 5%, emulsifying agent 5%, and the water of surplus, appropriate each raw material is weighed respectively；
Wherein, the thickener is glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, Pork and beans
Cool isopropyl propionate；
The emulsifying agent is triethanolamine
(a) glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, isopropyl myristate are mixed
Conjunction is heated to 65 DEG C, after raw material is completely dissolved, and stirs, and obtains thickener mixed system, and be incubated under the conditions of 65 DEG C；
(b) it is to be dissolved in 65 DEG C of water triethanolamine to be added into temperature, obtains triethanolamine solution；
(c) stirring and dissolving in the water of 80 DEG C of metronidazole, peppermint oil and goldenrod water extract addition, and in 80 DEG C of bars
It is incubated under part；
(d) after appropriate watery hydrochloric acid being heated into 60 DEG C, ketoconazole stirring and dissolving is added, and be incubated under the conditions of 60 DEG C；
(e) triethanolamine solution is added into 120r/min in thickener mixed system and stirs 10min, treat into sticky lotion
Afterwards, add step (c) and (d) resulting solution 120r/min and be stirred 40min, then cool down, that is, obtain doting on for embodiment 3
The externally-applied ointment of thing treating skin disease.
Embodiment 4
Externally-applied ointment is prepared with reference to the method for embodiment 1, obtains the externally-applied ointment of the pet skin disease treatment of embodiment 4；
Wherein, it is raw materials used as follows in embodiment 4 according to mass percentage：Ketoconazole 2%, metronidazole 1%, peppermint
Oil 2%, Herba Solidaginis extract 35%, thickener 5%, emulsifying agent 5%, and the water of surplus.
Embodiment 5
Externally-applied ointment is prepared with reference to the method for embodiment 2, obtains the externally-applied ointment of the pet skin disease treatment of embodiment 5；
Wherein, according to mass percent, each raw material dosage is as follows in embodiment 5：Ketoconazole 1%, metronidazole 1%, peppermint
Oil 2%, Herba Solidaginis extract 40%, thickener 6%, emulsifying agent 6%, and the water of surplus.
Embodiment 6
Externally-applied ointment is prepared with reference to the method for embodiment 3, obtains the externally-applied ointment of the pet skin disease treatment of embodiment 6；
Wherein, in the step (a) of embodiment 6, the temperature of thickener heating is 95 DEG C, and in the bar of 95 DEG C of insulations of thickener
Under part, the mixing of step (e) is carried out.
Comparative example 1
Externally-applied ointment is prepared with reference to the method for embodiment 1, obtains the externally-applied ointment of the pet skin disease treatment of comparative example 1；
Wherein, according to mass percent, each raw material dosage is as follows in comparative example 1：Ketoconazole 1%, metronidazole 2%, peppermint
Oil 1%, thickener 5%, emulsifying agent 5%, and the water of surplus.
Comparative example 2
Externally-applied ointment is prepared with reference to the method for embodiment 1, obtains the externally-applied ointment of the pet skin disease treatment of comparative example 2；
Wherein, according to mass percent, each raw material dosage is as follows in comparative example 2：Goldenrod leaf essential oil 70%, thickener
5%, emulsifying agent 5%, and the water of surplus.
Comparative example 3
With reference to the method for embodiment 2, the externally-applied ointment of the pet skin disease treatment of comparative example 3 is obtained；
Wherein, in comparative example 3, each raw material dosage is as follows：Ketoconazole 1%, metronidazole 2%, peppermint oil 1%, thickener
6%, emulsifying agent 6%, and the water of surplus.
Comparative example 4
With reference to the method for embodiment 2, the externally-applied ointment of the pet skin disease treatment of comparative example 4 is obtained；
Wherein, in comparative example 4, each raw material dosage is as follows：Metronidazole 3%, peppermint oil 2%, goldenrod volatile oil 40%,
Thickener 6%, emulsifying agent 6%, and the water of surplus.
Comparative example 5
With reference to the method for embodiment 3, the externally-applied ointment of the pet skin disease treatment of comparative example 5 is obtained；
Wherein, in comparative example 5, each raw material dosage is as follows：According to mass percent：Ketoconazole 1%, metronidazole 2%, peppermint
Oil 1%, thickener 5%, emulsifying agent 5%, and the water of surplus.
Comparative example 6
With reference to the method for embodiment 3, the externally-applied ointment of the pet skin disease treatment of comparative example 6 is obtained；
Wherein, in comparative example 6, each raw material dosage is as follows：Ketoconazole 3%, peppermint oil 1%, goldenrod water extract
50%, thickener 5%, emulsifying agent 5%, and the water of surplus.
Experimental example 1
(1) experimental animal：Somewhere Animal Shelter station suffers from the dermopathic adult miniature dog of fungal infectious after diagnosing, suffers from
Sick dog face, neck back, skin of abdomen flush, itching, different degrees of depilation occurs at infection, there are warts, skin in affected part
Thicken, it is ruddy and be in cerise to remove skin after crust；
Ill dog 220 is selected, ill dog is only randomly divided into 5 groups, 1-4 groups are to test 1-4 groups, every group 50；The
5 groups are negative control group, totally 20.
To the ill dog of 1-4 groups only respectively with embodiment 1, embodiment 4 and comparative example 1, the externally-applied ointment of comparative example 2
Treated, ointment is applied to affected part, it is daily to smear 2 times, every time using 5g or so ointment, continuous treatment 10 days；
Negative control group dog only smears vaseline in affected part；
Then, at the 11st day, therapeutic effect assessment is only carried out to each group dog, criterion is as follows：
Then, the horse in every dog affected part (or former affected part after recovery/part recovery) is detected using methylene blue decoration method
Color bacterium number amount is drawn, and treatment results are judged according to following standard：
(1) cure：Chlosma quantity is within control group par 10%；
(2) it is effective：Chlosma quantity is control group par 10~50%；
(3) effectively：Chlosma quantity is control group par 50~90%；
(4) it is invalid：Chlosma quantity is control group par more than 90%；
(5) it is efficient：(curing number+significant figure+effective number)/sum × 100%.
Then, respectively calculate and statistical experiment group dog therapeutic effect situation, it is as a result as follows：
| Experimental group | Cure (only) | Effective (only) | Effectively (only) | Invalid (only) | Efficient (%) |
| Embodiment 1 | 39 | 7 | 4 | 0 | 100 |
| Embodiment 4 | 31 | 9 | 5 | 5 | 90 |
| Comparative example 1 | 13 | 6 | 12 | 19 | 62 |
| Comparative example 2 | 6 | 5 | 9 | 30 | 40 |
| Control group | 0 | 0 | 0 | 20 | 0 |
From as above check experiment, skin infection of the externally-applied ointment of the present invention for small-sized dog has good treatment effect
Fruit, and can effectively kill fungi；
Meanwhile from the Contrast on effect of example 1,2 and comparative example 1,2 is performed as described above, composition of raw materials is for externally-applied ointment
Therapeutic effect has large effect, and is to be unable to reach satisfied treatment to imitate only using Herba Solidaginis extract as functional raw material
Fruit；Meanwhile only using ketoconazole, metronidazole, peppermint oil as the externally-applied ointment obtained by raw material, it is controlled for pet skin disease
Therapeutic effect as raw material using ketoconazole, metronidazole, peppermint oil, Herba Solidaginis extract in the present invention also substantially not as being used in combination institute
The effect that can reach.
Further, raw material dosage proportioning also has certain influence for therapeutic effect, and according to the scheme of embodiment 1
Raw material proportioning is carried out, the therapeutic effect that can reach is significantly superior.
(2) experimental animal：Somewhere Animal Shelter station suffers from the dermopathic adult cat of fungal infectious, ill cat after diagnosing
Face, neck back, skin of abdomen flush, itching, sick dog have sharp ears and root of the tail etc. cover a large amount of crusts and the scales of skin that peel off, Head And Face and
Break hair at body surface other positions, and circular hair removal section scurf is more；
Ill cat is only randomly divided into 5 groups, 1-4 groups every group 50, as experiment 1-4 groups, the 5th group 10, as right
According to group；
To the ill dog of 1-4 groups only respectively with outer prepared by embodiment 2, embodiment 5 and comparative example 3, comparative example 4
Treated with ointment, ointment is applied to affected part, daily to smear 2 times, continuous treatment 10 days；
Control group cat smears vaseline in affected part；
Then, in 11d, using methylene blue decoration method detect every cat affected part (or recovery/part recover after former suffer from
Place) chlosma quantity, and treatment results are judged according to following standard：
(1) cure：Chlosma quantity is within control group par 10%；
(2) it is effective：Chlosma quantity is control group par 10~50%；
(3) effectively：Chlosma quantity is control group par 50~90%；
(4) it is invalid：Chlosma quantity is control group par more than 90%；
Then, respectively calculate and statistical experiment group cat therapeutic effect situation, it is as a result as follows：
From data comparison as above, externally-applied ointment of the present invention has good sterilization for the dermopathic cat of trouble and controlled
Therapeutic effect；
Meanwhile from the Contrast on effect of embodiment 2,4 and comparative example 3,4, only with ketoconazole/metronidazole, peppermint oil, with
And therapeutic effect of the three kinds of components of Herba Solidaginis extract for the externally-applied ointment obtained by raw material for pet skin disease, hence it is evident that no
As soft as the external application prepared by raw material using four kinds of ketoconazole, metronidazole, peppermint oil, Herba Solidaginis extract components in the present invention
Cream.
(3) experimental animal：With the dermopathic large-scale dog of adult of fungal infectious, suffer from after diagnosing at somewhere Animal Shelter station
Sick dog face, neck back, skin of abdomen flush, itching, different degrees of depilation occurs at infection, there are warts, skin in affected part
Thicken, it is ruddy and be in cerise to remove skin after crust；
Ill dog is only randomly divided into 5 groups, 1-3 groups every group 50, as experiment 1-4 groups, the 5th group 10, as right
According to group；
To the ill dog of 1-4 groups only respectively with embodiment 3, embodiment 6 and comparative example 5, the externally-applied ointment of comparative example 6
Treated, ointment is applied to affected part, daily to smear 2 times, continuous treatment 10 days；
Control group dog smears vaseline in affected part；
Treatment phase is 10d, in 11d, experimental group and control group dog is only observed respectively, as a result found, control group
Dog scytitis does not change, and each experimental group dog skin substantially has different degrees of improvement；
Then, the horse traction in every dog affected part (or former affected part after recovery/part recovery) is detected using methylene blue decoration method
Color bacterium number amount, and treatment results are judged according to following standard：
(1) cure：Chlosma quantity is within control group par 10%；
(2) it is effective：Chlosma quantity is control group par 10~50%；
(3) effectively：Chlosma quantity is control group par 50~90%；
(4) it is invalid：Chlosma quantity is control group par more than 90%；
Then, respectively calculate and statistical experiment group dog therapeutic effect situation, it is as a result as follows：
| Experimental group | Cure (only) | Effectively (only) | Effective (only) | Invalid (only) | Efficient (%) |
| Embodiment 3 | 43 | 5 | 2 | 0 | 100 |
| Embodiment 6 | 41 | 2 | 4 | 3 | 94 |
| Comparative example 5 | 13 | 5 | 10 | 22 | 56 |
| Comparative example 6 | 20 | 8 | 7 | 15 | 70 |
| Control group | 0 | 0 | 0 | 10 | 0 |
From embodiment 3 and the Contrast on effect of comparative example 5, peppermint oil and ketoconazole, metronidazole and goldenrod are carried
More excellent pet skin disease therapeutic effect can be reached by taking thing to be used in combination.
(4) Example 1 and the compound ketoconazole ointment prepared by the method for comparative example 6 respectively, by commercially available back,
Placed 6 months under conditions of temperature (30 DEG C ± 2 DEG C), relative humidity (40% ± 5%).0th month during experiment, 1 month,
2 months, 3 months, 6 the end of month it is separately sampled once, press《Veterinary drug national standard compilation-veterinary drug provincial standard rises national standard
(the 3rd)》Compound ketoconazole ointment standard detected, Testing index：Character, Determination of Ketoconazole, metronidazole content.
And from as above stability test contrast, preparation method for the stability of externally-applied ointment of the present invention have compared with
Big influence, and according to the method for the embodiment of the present invention 3, control Aqueous Phase Raw Material temperature it is suitable with thickener mixed system temperature or
Higher than thickener temperature, the stability of prepared ointment can be effectively improved.
Although illustrate and describing the present invention with specific embodiment, but will be appreciated that without departing substantially from the present invention's
Many other change and modification can be made in the case of spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (10)
1. a kind of externally-applied ointment for pet skin disease treatment, it is characterised in that described for the outer of pet skin disease treatment
Mainly it is made up with ointment of following components：
Ketoconazole, metronidazole, peppermint oil, Herba Solidaginis extract, and auxiliary material；
Preferably, the Herba Solidaginis extract is that goldenrod water extract, goldenrod leaf essential oil, or goldenrod are waved
One or more of mixtures in hair oil.
2. the externally-applied ointment according to claim 1 for pet skin disease treatment, it is characterised in that the auxiliary material includes
Thickener, emulsifying agent and water.
3. the externally-applied ointment according to claim 2 for pet skin disease treatment, it is characterised in that the emulsifying agent bag
Include：One or more in lauryl sodium sulfate, Tween-80, Arlacel-80, or triethanolamine；
And/or the thickener includes：Glycerin monostearate, stearyl alcohol, vaseline, atoleine, vitamin E oil, Pork and beans
It is one or more of in cool isopropyl propionate.
4. the externally-applied ointment according to claim 1 for pet skin disease treatment, it is characterised in that according to weight percent
Number meter, the externally-applied ointment for pet skin disease treatment are mainly made up of following components：
Ketoconazole 1~10%, metronidazole 1~10%, peppermint oil 1~10%, Herba Solidaginis extract 5~50%, and auxiliary material
20~90%.
5. the externally-applied ointment according to claim 4 for pet skin disease treatment, it is characterised in that according to weight percent
Number meter, the externally-applied ointment for pet skin disease treatment are mainly made up of following components：
Ketoconazole 1~10%, metronidazole 1~10%, peppermint oil 1~10%, Herba Solidaginis extract 5~50%, thickener 2~
30%, emulsifying agent 1~10%, and water 15~50%.
6. the preparation method of the externally-applied ointment for being used for pet skin disease treatment any one of claim 1-5, its feature
It is, the preparation method comprises the following steps：
Mix, stir after each component is dissolved respectively, sticky lotion is obtained after cooling, be described sick for pet skin
The externally-applied ointment for the treatment of.
7. preparation method according to claim 6, it is characterised in that the preparation method comprises the following steps：
(a) after thickener is mixed, it is heated to being completely dissolved, stirs, obtains thickener mixed system；
(b) emulsifying agent is added into stirring and dissolving in the water after heating, then adds metronidazole, peppermint oil and goldenrod extraction
Thing, stirring and dissolving；
(c) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
(d) step (b), (c) resulting solution are added in thickener mixed system, stir and evenly mix, sticky lotion is obtained after cooling,
As it is used for the externally-applied ointment of pet skin disease treatment.
8. preparation method according to claim 6, it is characterised in that the preparation method comprises the following steps：
(a) after mixing emulsifying agent, thickener, it is heated to raw material and is completely dissolved, stir, obtain thickener mixed system；
(b) metronidazole, peppermint oil and Herba Solidaginis extract are added into stirring and dissolving in the water after heating；
(c) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
(d) step (b), (c) resulting solution are added in thickener mixed system, are stirred, sticky lotion is obtained after cooling,
As it is used for the externally-applied ointment of pet skin disease treatment.
9. preparation method according to claim 6, it is characterised in that the preparation method comprises the following steps：
(a) after thickener is mixed, it is heated to raw material and is completely dissolved, stir, obtains thickener mixed system；
(b) dissolved in the water for adding emulsifying agent after heating, obtain emulsifier solution；
(c) metronidazole, peppermint oil and Herba Solidaginis extract are added into stirring and dissolving in the water after heating；
(d) after watery hydrochloric acid is heated, ketoconazole stirring and dissolving is added；
(e) emulsifier solution is added in thickener mixed system and stirred, then, add step (c), the stirring of (d) resulting solution
Mixing, sticky lotion, the as externally-applied ointment for pet skin disease treatment are obtained after cooling.
10. include the medicine or medicine of the externally-applied ointment for being used for pet skin disease treatment any one of claim 1-5
Composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710903023.7A CN107648308A (en) | 2017-09-29 | 2017-09-29 | A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710903023.7A CN107648308A (en) | 2017-09-29 | 2017-09-29 | A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107648308A true CN107648308A (en) | 2018-02-02 |
Family
ID=61116720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710903023.7A Withdrawn CN107648308A (en) | 2017-09-29 | 2017-09-29 | A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648308A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440477A (en) * | 2021-08-12 | 2021-09-28 | 海南海神同洲制药有限公司 | Low-viscosity ketoconazole cream and preparation method thereof |
| CN116159096A (en) * | 2023-03-23 | 2023-05-26 | 江苏朗博特动物药品有限公司 | Compound ketoconazole preparation for pets and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283850A (en) * | 2011-08-25 | 2011-12-21 | 西北农林科技大学 | Oil-in-water type compound ketoconazole nano-medicament and preparation method thereof |
-
2017
- 2017-09-29 CN CN201710903023.7A patent/CN107648308A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283850A (en) * | 2011-08-25 | 2011-12-21 | 西北农林科技大学 | Oil-in-water type compound ketoconazole nano-medicament and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 朱要宏: "《犬猫临床用药手册》", 31 October 2015, 中国农业出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440477A (en) * | 2021-08-12 | 2021-09-28 | 海南海神同洲制药有限公司 | Low-viscosity ketoconazole cream and preparation method thereof |
| CN113440477B (en) * | 2021-08-12 | 2022-10-11 | 海南海神同洲制药有限公司 | Low-viscosity ketoconazole cream and preparation method thereof |
| CN116159096A (en) * | 2023-03-23 | 2023-05-26 | 江苏朗博特动物药品有限公司 | Compound ketoconazole preparation for pets and preparation method thereof |
| CN116159096B (en) * | 2023-03-23 | 2023-11-03 | 江苏朗博特动物药品有限公司 | Compound ketoconazole preparation for pets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462881B (en) | A kind of composition and method of making the same promoting skin microecological balance | |
| CN103142908B (en) | Spray for Killing Mites on Body Surface of Pet and Preparation Method of Spray | |
| CN110585114B (en) | Bactericidal composition for regulating skin microbial flora and application thereof | |
| CN104435379B (en) | A kind of plant extract complex with antibacterial anti-inflammatory, hemostasis and pain relieving and application thereof | |
| CN104688786B (en) | A kind of externally-applied medicinal composition and its preparation method and application | |
| CN106342925A (en) | Biological pesticide specially used for eggplants, and preparation method of biological pesticide | |
| JPH06279256A (en) | Skin external preparation | |
| CN108078863A (en) | A kind of bactericidal composition and Baby Care composition based on plant extracts | |
| KR20170040002A (en) | Cosmetic Composion for Acne Improvement Containing Butanol Fraction of Red Ginseng Ethanol Extract | |
| CN1860910A (en) | Synergist made of Chinese herb medicine for forage to feed domestic animals, domestic birds and fish or like | |
| CN107551274A (en) | A kind of animal antifungal preparation and preparation method thereof | |
| CN112043817A (en) | Anti-mite composition and application thereof | |
| CN107648308A (en) | A kind of externally-applied ointment for pet skin disease treatment and preparation method thereof | |
| JP2019178170A (en) | Use of patchouli extract in preparation of compositions with anti-microorganism effect | |
| CN101559035B (en) | Plant extract composition for killing fungi, preparation method thereof and application in preparing antifungal products | |
| CN102144728A (en) | Preparation method of honeysuckle extract feed additive | |
| CN106305517A (en) | Culture method capable of reducing red skin disease and green liver disease of grass carps | |
| CN106727026B (en) | Traditional Chinese medicine acne-removing composition and application thereof | |
| CN113398237A (en) | Traditional Chinese medicine composition with antibacterial, itching relieving and dandruff stopping functions and preparation method thereof | |
| CN112773733A (en) | Acne-removing composition and preparation method of emulsion thereof | |
| KR20150045599A (en) | An antifungal composition comprising an natural fermentation material | |
| CN109200137A (en) | A kind of tea oil bacteriostatic agent and preparation method thereof | |
| CN107349165A (en) | A kind of acne preventing and treating additive and its application | |
| CN106344453A (en) | Novel acne cream and preparation method thereof | |
| CN101879223A (en) | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180202 |
|
| WW01 | Invention patent application withdrawn after publication |